PRODUCT DEVELOPMENT PIPELINE

RegeneRx drug candidates are the subject of 4 late stage clinical trials in the U.S., China and Korea for patients with dry eye syndrome and neurotrophic keratopathy (an orphan indication in the U.S.). We expect the results of these trials to be available by the end of 2015 through 2016.


print email